Current Report Filing (8-k)
December 08 2022 - 04:32PM
Edgar (US Regulatory)
false 0001759138 0001759138 2022-12-08
2022-12-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
December 8, 2022
Date of Report (Date of earliest event reported)
CABALETTA BIO, INC.
(Exact name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware |
|
001-39103 |
|
82-1685768 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
2929 Arch Street, Suite 600,
Philadelphia, PA
|
|
|
|
19104 |
(Address of principal executive
offices) |
|
|
|
(Zip Code) |
(267) 759-3100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of Each Class
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange
on Which Registered
|
Common Stock, par value $0.00001 per share |
|
CABA |
|
The
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On December 8, 2022, Cabaletta Bio, Inc. (the “Company”) posted to the
“Investors & Media” section of the Company’s website at
www.cabalettabio.com an
updated corporate presentation providing a corporate overview and
updated development plan (the “Corporate Presentation”). A copy of the
Corporate Presentation is attached hereto as Exhibit 99.1 and is
incorporated by reference into this Item 8.01 of this Current
Report on Form 8-K.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
CABALETTA BIO, INC. |
|
|
|
|
Date: December 8, 2022 |
|
|
|
By: |
|
/s/ Steven Nichtberger
|
|
|
|
|
|
|
Steven Nichtberger, M.D. |
|
|
|
|
|
|
President and Chief Executive
Officer |
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From May 2023 to Jun 2023
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jun 2022 to Jun 2023